MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.94 -3.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.91

Max

9.48

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+147.14% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	129M 878M
Ankstesnė atidarymo kaina	12.29
Ankstesnė uždarymo kaina	8.94

Naujienos nuotaikos

By Acuity

92%

4 / 370 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-09 22:18; UTC

Rinkos pokalbiai

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-01-09 21:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

2026-01-09 20:39; UTC

Rinkos pokalbiai

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

2026-01-09 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

2026-01-09 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

2026-01-09 20:30; UTC

Rinkos pokalbiai

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

2026-01-09 20:15; UTC

Rinkos pokalbiai

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

2026-01-09 20:07; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-09 20:07; UTC

Rinkos pokalbiai

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

2026-01-09 19:58; UTC

Įsigijimai, susijungimai, perėmimai

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026-01-09 19:42; UTC

Rinkos pokalbiai

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

2026-01-09 19:38; UTC

Įsigijimai, susijungimai, perėmimai

Wolters Kluwer Acquires StandardFusion >WTKWY

2026-01-09 19:31; UTC

Uždarbis

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

2026-01-09 19:28; UTC

Uždarbis

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

2026-01-09 18:30; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

2026-01-09 18:23; UTC

Rinkos pokalbiai

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

2026-01-09 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-09 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-09 17:19; UTC

Rinkos pokalbiai

Energy Prices Not Seen Supporting More Drilling -- Market Talk

2026-01-09 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-01-09 17:07; UTC

Rinkos pokalbiai

McDonald's Promotions Appear Successful -- Market Talk

2026-01-09 17:06; UTC

Rinkos pokalbiai

Oil Futures on Track for Weekly Gains -- Market Talk

2026-01-09 17:05; UTC

Uždarbis

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

2026-01-09 16:57; UTC

Rinkos pokalbiai

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

2026-01-09 16:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-09 16:46; UTC

Rinkos pokalbiai

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

147.14% į viršų

12 mėnesių prognozė

Vidutinis 23.75 USD 147.14%

Aukščiausias 34 USD

Žemiausias 16 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

4 / 370 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.